TIVICAY is a brand name for the antiretroviral medication dolutegravir, which is used in the treatment of human immunodeficiency virus (HIV) infection. As an integrase strand transfer inhibitor (INSTI), TIVICAY works by blocking the HIV integrase enzyme. This action prevents the viral DNA from integrating into the genetic material of human immune cells (T-cells), which is a critical step in the HIV replication cycle. By halting this process, dolutegravir helps to control HIV infection and reduce the viral load in the body, allowing the immune system to recover and reducing the risk of HIV-related illnesses. TIVICAY is often used in combination with other antiretroviral medications as part of an antiretroviral therapy (ART) regimen. It is known for its efficacy, convenience of dosing, and a generally favorable side effect profile, making it a key component in the management of HIV.